| CAS | 283609-79-0 |
| Sequence | H-Leu-Ser-Lys-Leu-NH2 |
| Sequence Single | LSKL-NH2 |
| Molecular Formula | C21H42N6O5 |
| Molecular Weight | 458.6 |
| Synonyms | Inhibitor of Thrombospondin (TSP-1) |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Growth Factors|Hematology |
| Description | H-Leu-Ser-Lys-Leu-NH2 also called Inhibitor of Thrombospondin (TSP-1), is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. H-Leu-Ser-Lys-Leu-NH2 inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. H-Leu-Ser-Lys-Leu-NH2 suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). H-Leu-Ser-Lys-Leu-NH2 can readily crosse the blood-brain barrier. |
| References | 1. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Liao F, et al. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31. 2. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Laurent MA, et al. Comput Biol Chem. 2016 Apr;61:155-61. 3. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Kuroki H, et al. Br J Surg. 2015 Jun;102(7):813-25. |